Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Its lead candidate, zenocutuzumab, currently in Phase I/II development and available via an Early Access Program, is a bispecific antibody with a HER2/HER3 target combination directed at NRG1 fusions, a rare driver of cancer cell growth. The company is headquartered in Utrecht, the Netherlands